AAV8-Mediated Retinal PD-L1 Gene Transfer Attenuates Experimental Autoimmune Uveitis by Restoring Local Immune Tolerance
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.8.17 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Quanxi Lai and 7 co-authors. Institution: National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, China. Major MEDLINE topics: Autoimmune Diseases, Uveitis, Dependovirus, Immune Tolerance. 38 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
To investigate the therapeutic potential of the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immune checkpoint pathway in experimental autoimmune uveitis (EAU) and to elucidate its role in regulating the retinal immune microenvironment.
Methods
Seven days before EAU induction, Lewis rats received subretinal injections of adeno-associated virus serotype 8 (AAV8)/PD-L1. EAU was induced by immunization with interphotoreceptor retinoid-binding protein (IRBP) in complete Freund's adjuvant. Clinical inflammation scores were recorded on days 8, 10, 12, and 14 post-immunizations. Retinal function was evaluated by electroretinography (ERG) on day 12, and structural changes were assessed by optical coherence tomography (OCT). On day 14, eyes were harvested for histopathological examination, immunofluorescence, and flow cytometric analyses of leukocyte infiltration and cytokine expression. Normal rats injected with AAV8/PD-L1 were examined to assess retinal safety.
Results
AAV8/PD-L1 markedly enhanced PD-L1 expression in the retina, resulting in significantly reduced intraocular inflammation and tissue damage compared with untreated EAU rats. The PD-L1 group showed lower anterior chamber inflammation scores (P < 0.05), decreased retinal T-cell and leukocyte infiltration (P < 0.05), and downregulated expression of IL-17. No structural or functional abnormalities were observed in normal eyes treated with AAV8/PD-L1.
Conclusions
AAV8-mediated PD-L1 overexpression suppresses EAU progression by restoring retinal immune tolerance, attenuating inflammation, and preserving visual function. This approach offers a promising gene therapy strategy for local immune modulation in ocular autoimmune diseases.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
- State Key Laboratory of Eye Health, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
- National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
- Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
Cite
APA
Lai, Q., Jin, Y., Ding, J., Jiang, P., Fang, L., Wang, Y., Li, X., & Shi, S. (2026). AAV8-Mediated Retinal PD-L1 Gene Transfer Attenuates Experimental Autoimmune Uveitis by Restoring Local Immune Tolerance. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.8.17
Vancouver
Lai Q, Jin Y, Ding J, Jiang P, Fang L, Wang Y, et al. AAV8-Mediated Retinal PD-L1 Gene Transfer Attenuates Experimental Autoimmune Uveitis by Restoring Local Immune Tolerance. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.8.17
BibTeX
@article{Lai2026,
author = {Lai, Quanxi and Jin, Yuanyuan and Ding, Jingjie and Jiang, Piao and Fang, Linyue and Wang, Yuqin and Li, Xingyi and Shi, Shuai},
title = {AAV8-Mediated Retinal PD-L1 Gene Transfer Attenuates Experimental Autoimmune Uveitis by Restoring Local Immune Tolerance},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.8.17}
}
EUVIMED